Inspire Investing’s Supernus Pharmaceuticals SUPN Stock Holding History

Inspire Investing’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,349	Closed	-$213K	–	834
2022 Q2	$213K	Buy	7,349 +5	+0.1%	+$143	0.03%	451
2022 Q1	$237K	Sell	7,344 -1,034	-12%	-$31.7K	0.03%	446
2021 Q4	$244K	Sell	8,378 -70	-0.8%	-$2.12K	0.03%	751
2021 Q3	$225K	Sell	8,448 -3,960	-32%	-$106K	0.03%	712
2021 Q2	$382K	Buy	12,408 +376	+3%	+$11.5K	0.05%	465
2021 Q1	$315K	Buy	12,032 +2,608	+28%	+$72.9K	0.05%	510
2020 Q4	$237K	Buy	+9,424	New	+$203K	0.05%	555
2020 Q3	–	Sell	-9,052	Closed	-$215K	–	561
2020 Q2	$215K	Sell	9,052 -3,776	-29%	-$83.4K	0.07%	413
2020 Q1	$231K	Buy	+12,828	New	+$270K	0.09%	325
2018 Q1	–	Sell	-1,426	Closed	-$57K	–	637
2017 Q4	$57K	Buy	+1,426	New	+$56.3K	0.05%	490

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Inspire Investing's SUPN Position: Q3 2022 in Review

Inspire Investing sold out of Supernus Pharmaceuticals (SUPN) in Q3 2022, closing a stake of 7,349 shares — an estimated $213K sold.

Inspire Investing first reported a position in SUPN in Q4 2017 and held it in 10 quarters. The position peaked at $382K in Q2 2021. 244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

Inspire Investing reported no remaining Supernus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Inspire Investing sold 7,349 Supernus Pharmaceuticals shares in Q3 2022, an estimated $213K.
Inspire Investing first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Inspire Investing's Supernus Pharmaceuticals position peaked at $382K in Q2 2021.
244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on Inspire Investing's 13F filing for Q3 2022, filed 7 Nov 2022.